Baylor College of Medicine

A Phase 3 Randomized Controlled Trial of Ladarixin in New-Onset Type 1 Diabetes (H-49339)

Description

Content

Study Goal(s): This is a phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of 400 mg twice a day oral ladaraxin in patients with new-onset type 1 diabetes and a low residual β-cell function at baseline. 

Eligibility criteria: 14-20 years old adolescents and young adults with new-onset type 1 diabetes (BCM/TCH Criteria) 

Investigators: Mustafa Tosur, M.D. (site principal investigator), Maria J. Redondo, M.D., Ph.D. (co-investigator), Serife Uysal, M.D. (co-investigator), Tracy Patel, M.D. (co-investigator)

Supported by: Dompe Pharmaceuticals

Contact

saima.deen@bcm.edu

IRB: H-49339

Status:

Active

Created:

Back to topback-to-top